View Past PerformanceEgyptian International Pharmaceutical Industries バランスシートの健全性財務の健全性 基準チェック /26Egyptian International Pharmaceutical Industriesの総株主資本はEGP5.7B 、総負債はEGP9.4Bで、負債比率は165.8%となります。総資産と総負債はそれぞれEGP18.4BとEGP12.8Bです。 Egyptian International Pharmaceutical Industriesの EBIT はEGP2.3Bで、利息カバレッジ比率2.1です。現金および短期投資はEGP362.8Mです。主要情報165.75%負債資本比率ج.م9.42b負債インタレスト・カバレッジ・レシオ2.1x現金ج.م362.82mエクイティج.م5.68b負債合計ج.م12.75b総資産ج.م18.43b財務の健全性に関する最新情報更新なしすべての更新を表示Recent updatesNew Risk • May 29New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.1x net interest cover). High level of non-cash earnings (22% accrual ratio). Minor Risk Paying a dividend despite having no free cash flows.Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Director Ahmed El Sayed Layla was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Mar 05Egyptian International Pharmaceutical Industries Company, Annual General Meeting, Mar 28, 2026Egyptian International Pharmaceutical Industries Company, Annual General Meeting, Mar 28, 2026, at 12:00 Egypt Standard Time. Location: cairo EgyptReported Earnings • May 16First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: ج.م2.30b (up 53% from 1Q 2024). Net income: ج.م318.6m (down 47% from 1Q 2024). Profit margin: 14% (down from 40% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Pharmaceuticals industry in Africa. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 17% per year.Board Change • May 14No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Director Ahmed El Sayed Layla was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Mar 05Egyptian International Pharmaceutical Industries Company, Annual General Meeting, Mar 26, 2025Egyptian International Pharmaceutical Industries Company, Annual General Meeting, Mar 26, 2025, at 14:00 Egypt Standard Time. Location: cairo EgyptReported Earnings • Nov 16Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: ج.م2.07b (up 47% from 3Q 2023). Net income: ج.م204.9m (up 52% from 3Q 2023). Profit margin: 9.9% (in line with 3Q 2023).Price Target Changed • Nov 14Price target increased by 15% to ج.م69.46Up from ج.م60.53, the current price target is an average from 3 analysts. New target price is 44% above last closing price of ج.م48.11. Stock is up 27% over the past year. The company posted earnings per share of ج.م5.53 last year.Reported Earnings • Aug 17Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: ج.م1.88b (up 47% from 2Q 2023). Net income: ج.م175.6m (down 45% from 2Q 2023). Profit margin: 9.3% (down from 25% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Africa. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Buy Or Sell Opportunity • Aug 04Now 21% undervaluedOver the last 90 days, the stock has risen 5.2% to ج.م37.85. The fair value is estimated to be ج.م48.12, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 14%. Revenue is forecast to grow by 29% in a year. Earnings are forecast to decline by 25% in the next year.お知らせ • Aug 01Egyptian International Pharmaceutical Industries Company(CASE:PHAR) dropped from EGX 30 IndexEgyptian International Pharmaceutical Industries Company has been dropped from EGX 30 Index.Valuation Update With 7 Day Price Move • May 02Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ج.م35.00, the stock trades at a trailing P/E ratio of 6.3x. Average forward P/E is 12x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 34% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ج.م38.38 per share.Upcoming Dividend • Apr 24Upcoming dividend of ج.م2.00 per shareEligible shareholders must have bought the stock before 28 April 2024. Payment date: 29 August 2024. Payout ratio is a comfortable 18% but the company is not cash flow positive. Trailing yield: 2.3%. Lower than top quartile of Egyptian dividend payers (6.8%). Lower than average of industry peers (3.0%).Declared Dividend • Apr 10Dividend of ج.م2.00 announcedShareholders will receive a dividend of ج.م2.00. Ex-date: 25th April 2024 Payment date: 29th August 2024 Dividend yield will be 4.6%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is covered by earnings (17% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 76 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 3.5% over the last 3 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.Buy Or Sell Opportunity • Mar 20Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 28% to ج.م49.35. The fair value is estimated to be ج.م40.62, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 8.8%. Revenue is forecast to grow by 45% in 2 years. Earnings are forecast to grow by 32% in the next 2 years.Buy Or Sell Opportunity • Mar 03Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 14% to ج.م49.00. The fair value is estimated to be ج.م40.62, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 12%. Revenue is forecast to grow by 36% in 2 years. Earnings are forecast to grow by 19% in the next 2 years.Price Target Changed • Feb 29Price target increased by 19% to ج.م72.20Up from ج.م60.53, the current price target is an average from 3 analysts. New target price is 47% above last closing price of ج.م49.20. Stock is up 40% over the past year. The company posted earnings per share of ج.م6.48 last year.New Risk • Nov 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 50% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 1.7% per year over the past 5 years. High level of non-cash earnings (50% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Shareholders have been diluted in the past year (50% increase in shares outstanding).Valuation Update With 7 Day Price Move • Aug 28Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ج.م32.81, the stock trades at a trailing P/E ratio of 4.9x. Average forward P/E is 15x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 17% over the past three years.New Risk • Jun 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Egyptian stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 6.3% per year over the past 5 years. High level of non-cash earnings (30% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (ج.م2.64b market cap, or US$85.3m).Valuation Update With 7 Day Price Move • May 11Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ج.م26.36, the stock trades at a trailing P/E ratio of 4.1x. Average forward P/E is 18x in the Pharmaceuticals industry in Egypt. Total loss to shareholders of 29% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ج.م32.16 per share.Reported Earnings • Apr 08Full year 2022 earnings releasedFull year 2022 results: Revenue: ج.م3.96b (up 15% from FY 2021). Net income: ج.م643.0m (up 23% from FY 2021). Profit margin: 16% (up from 15% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Pharmaceuticals industry in Africa.Valuation Update With 7 Day Price Move • Feb 22Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ج.م34.71, the stock trades at a trailing P/E ratio of 5.8x. Average forward P/E is 18x in the Pharmaceuticals industry in Egypt. Total loss to shareholders of 40% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ج.م34.36 per share.Price Target Changed • Nov 25Price target decreased to ج.م63.87Down from ج.م71.53, the current price target is an average from 3 analysts. New target price is 99% above last closing price of ج.م32.12. Stock is down 15% over the past year. The company posted earnings per share of ج.م5.27 last year.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Director Ahmed El Sayed Layla was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Aug 13Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: ج.م834.7m (up 8.3% from 2Q 2021). Net income: ج.م118.2m (up 28% from 2Q 2021). Profit margin: 14% (up from 12% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 17%, compared to a 12% growth forecast for the industry in Egypt.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Director Ahmed El Sayed Layla was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Nov 12Third quarter 2021 earnings releasedThe company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: ج.م899.3m (up 27% from 3Q 2020). Net income: ج.م87.8m (up 14% from 3Q 2020). Profit margin: 9.8% (down from 11% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.Reported Earnings • Aug 14Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ج.م770.9m (up 12% from 2Q 2020). Net income: ج.م92.5m (up 325% from 2Q 2020). Profit margin: 12% (up from 3.2% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings.Upcoming Dividend • Apr 18Inaugural dividend of ج.م2.95 per shareEligible shareholders must have bought the stock before 25 April 2021. Payment date: 28 April 2021. The company last paid an ordinary dividend in March 2018. The average dividend yield among industry peers is 4.3%.Price Target Changed • Mar 25Price target decreased to ج.م64.07Down from ج.م68.90, the current price target is an average from 3 analysts. New target price is 49% above last closing price of ج.م43.12. Stock is down 26% over the past year.Is New 90 Day High Low • Jan 18New 90-day low: ج.م42.53The company is down 10.0% from its price of ج.م47.00 on 20 October 2020. The Egyptian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ج.م36.24 per share.Analyst Estimate Surprise Post Earnings • Nov 18Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 2.6%. Earnings per share (EPS) exceeded analyst estimates by 2.8%. Over the next year, revenue is forecast to grow 14%, compared to a 7.5% growth forecast for the Pharmaceuticals industry in Egypt.Is New 90 Day High Low • Nov 16New 90-day high: ج.م48.51The company is up 2.0% from its price of ج.م47.60 on 18 August 2020. The Egyptian market is up 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ج.م31.61 per share.Is New 90 Day High Low • Sep 30New 90-day low: ج.م45.00The company is down 15% from its price of ج.م52.90 on 30 June 2020. The Egyptian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ج.م31.61 per share.財務状況分析短期負債: PHARの 短期資産 ( EGP8.9B ) が 短期負債 ( EGP8.5B ) を超えています。長期負債: PHARの短期資産 ( EGP8.9B ) が 長期負債 ( EGP4.3B ) を上回っています。デット・ツー・エクイティの歴史と分析負債レベル: PHARの 純負債対資本比率 ( 159.4% ) は 高い と見なされます。負債の削減: PHARの負債対資本比率は、過去 5 年間で56.4%から165.8%に増加しました。債務返済能力: PHARの 営業キャッシュフロー はマイナスであるため、負債は十分にカバーされていません。インタレストカバレッジ: PHARの負債に対する 利息支払い は EBIT ( 2.1 x coverage) によって 十分にカバーされていません。貸借対照表健全な企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の健全な企業。View Dividend企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/07 07:54終値2026/06/07 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Egyptian International Pharmaceutical Industries Company 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Michel SaidCI Capital ResearchAhmed MoatazEFG-Hermes ResearchNematAllah ChoucriHC Brokerage2 その他のアナリストを表示
New Risk • May 29New major risk - Earnings qualityThe company has a high level of non-cash earnings. Accrual ratio: 22% This is considered a major risk. Non-cash earnings can arise from many different things. However, if a company consistently has a high level of non-cash earnings, it may be a sign that they are recognizing revenue from customers before the full value of the sales are received as cash or they are not depreciating the value of their assets appropriately. These are practices that inflate earnings, while not providing a similar increase to cash flows. Companies in some select industries naturally have a high level of non-cash earnings and it is not a major concern. However, in the worst case scenario it can be an early sign of performance manipulation by management. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (2.1x net interest cover). High level of non-cash earnings (22% accrual ratio). Minor Risk Paying a dividend despite having no free cash flows.
Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Director Ahmed El Sayed Layla was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Mar 05Egyptian International Pharmaceutical Industries Company, Annual General Meeting, Mar 28, 2026Egyptian International Pharmaceutical Industries Company, Annual General Meeting, Mar 28, 2026, at 12:00 Egypt Standard Time. Location: cairo Egypt
Reported Earnings • May 16First quarter 2025 earnings releasedFirst quarter 2025 results: Revenue: ج.م2.30b (up 53% from 1Q 2024). Net income: ج.م318.6m (down 47% from 1Q 2024). Profit margin: 14% (down from 40% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 5.0% growth forecast for the Pharmaceuticals industry in Africa. Over the last 3 years on average, earnings per share has increased by 14% per year whereas the company’s share price has increased by 17% per year.
Board Change • May 14No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Director Ahmed El Sayed Layla was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Mar 05Egyptian International Pharmaceutical Industries Company, Annual General Meeting, Mar 26, 2025Egyptian International Pharmaceutical Industries Company, Annual General Meeting, Mar 26, 2025, at 14:00 Egypt Standard Time. Location: cairo Egypt
Reported Earnings • Nov 16Third quarter 2024 earnings releasedThird quarter 2024 results: Revenue: ج.م2.07b (up 47% from 3Q 2023). Net income: ج.م204.9m (up 52% from 3Q 2023). Profit margin: 9.9% (in line with 3Q 2023).
Price Target Changed • Nov 14Price target increased by 15% to ج.م69.46Up from ج.م60.53, the current price target is an average from 3 analysts. New target price is 44% above last closing price of ج.م48.11. Stock is up 27% over the past year. The company posted earnings per share of ج.م5.53 last year.
Reported Earnings • Aug 17Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: ج.م1.88b (up 47% from 2Q 2023). Net income: ج.م175.6m (down 45% from 2Q 2023). Profit margin: 9.3% (down from 25% in 2Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in Africa. Over the last 3 years on average, earnings per share has increased by 16% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Buy Or Sell Opportunity • Aug 04Now 21% undervaluedOver the last 90 days, the stock has risen 5.2% to ج.م37.85. The fair value is estimated to be ج.م48.12, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 23% over the last 3 years. Earnings per share has grown by 14%. Revenue is forecast to grow by 29% in a year. Earnings are forecast to decline by 25% in the next year.
お知らせ • Aug 01Egyptian International Pharmaceutical Industries Company(CASE:PHAR) dropped from EGX 30 IndexEgyptian International Pharmaceutical Industries Company has been dropped from EGX 30 Index.
Valuation Update With 7 Day Price Move • May 02Investor sentiment deteriorates as stock falls 16%After last week's 16% share price decline to ج.م35.00, the stock trades at a trailing P/E ratio of 6.3x. Average forward P/E is 12x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 34% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ج.م38.38 per share.
Upcoming Dividend • Apr 24Upcoming dividend of ج.م2.00 per shareEligible shareholders must have bought the stock before 28 April 2024. Payment date: 29 August 2024. Payout ratio is a comfortable 18% but the company is not cash flow positive. Trailing yield: 2.3%. Lower than top quartile of Egyptian dividend payers (6.8%). Lower than average of industry peers (3.0%).
Declared Dividend • Apr 10Dividend of ج.م2.00 announcedShareholders will receive a dividend of ج.م2.00. Ex-date: 25th April 2024 Payment date: 29th August 2024 Dividend yield will be 4.6%, which is higher than the industry average of 2.8%. Sustainability & Growth Dividend is covered by earnings (17% earnings payout ratio) but the company has no free cash flows available, indicating it may be using cash reserves or debt to pay the dividend. The dividend has decreased over the past 76 years, indicating a lack of growth and stability in payments. Earnings per share has grown by 3.5% over the last 3 years. Unless this trend reverses, it should provide support to the dividend and adequate earnings cover.
Buy Or Sell Opportunity • Mar 20Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 28% to ج.م49.35. The fair value is estimated to be ج.م40.62, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 20% over the last 3 years. Earnings per share has grown by 8.8%. Revenue is forecast to grow by 45% in 2 years. Earnings are forecast to grow by 32% in the next 2 years.
Buy Or Sell Opportunity • Mar 03Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 14% to ج.م49.00. The fair value is estimated to be ج.م40.62, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 17% over the last 3 years. Earnings per share has grown by 12%. Revenue is forecast to grow by 36% in 2 years. Earnings are forecast to grow by 19% in the next 2 years.
Price Target Changed • Feb 29Price target increased by 19% to ج.م72.20Up from ج.م60.53, the current price target is an average from 3 analysts. New target price is 47% above last closing price of ج.م49.20. Stock is up 40% over the past year. The company posted earnings per share of ج.م6.48 last year.
New Risk • Nov 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 50% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 1.7% per year over the past 5 years. High level of non-cash earnings (50% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Shareholders have been diluted in the past year (50% increase in shares outstanding).
Valuation Update With 7 Day Price Move • Aug 28Investor sentiment improves as stock rises 20%After last week's 20% share price gain to ج.م32.81, the stock trades at a trailing P/E ratio of 4.9x. Average forward P/E is 15x in the Pharmaceuticals industry in Egypt. Total returns to shareholders of 17% over the past three years.
New Risk • Jun 18New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Egyptian stocks, typically moving 7.1% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Earnings have declined by 6.3% per year over the past 5 years. High level of non-cash earnings (30% accrual ratio). Minor Risks Paying a dividend despite having no free cash flows. Share price has been volatile over the past 3 months (7.1% average weekly change). Market cap is less than US$100m (ج.م2.64b market cap, or US$85.3m).
Valuation Update With 7 Day Price Move • May 11Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ج.م26.36, the stock trades at a trailing P/E ratio of 4.1x. Average forward P/E is 18x in the Pharmaceuticals industry in Egypt. Total loss to shareholders of 29% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ج.م32.16 per share.
Reported Earnings • Apr 08Full year 2022 earnings releasedFull year 2022 results: Revenue: ج.م3.96b (up 15% from FY 2021). Net income: ج.م643.0m (up 23% from FY 2021). Profit margin: 16% (up from 15% in FY 2021). The increase in margin was driven by higher revenue. Revenue is forecast to grow 14% p.a. on average during the next 3 years, compared to a 8.7% growth forecast for the Pharmaceuticals industry in Africa.
Valuation Update With 7 Day Price Move • Feb 22Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ج.م34.71, the stock trades at a trailing P/E ratio of 5.8x. Average forward P/E is 18x in the Pharmaceuticals industry in Egypt. Total loss to shareholders of 40% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ج.م34.36 per share.
Price Target Changed • Nov 25Price target decreased to ج.م63.87Down from ج.م71.53, the current price target is an average from 3 analysts. New target price is 99% above last closing price of ج.م32.12. Stock is down 15% over the past year. The company posted earnings per share of ج.م5.27 last year.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Director Ahmed El Sayed Layla was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 13Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: ج.م834.7m (up 8.3% from 2Q 2021). Net income: ج.م118.2m (up 28% from 2Q 2021). Profit margin: 14% (up from 12% in 2Q 2021). The increase in margin was driven by higher revenue. Over the next year, revenue is forecast to grow 17%, compared to a 12% growth forecast for the industry in Egypt.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 9 experienced directors. No highly experienced directors. No independent directors (9 non-independent directors). Director Ahmed El Sayed Layla was the last director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 12Third quarter 2021 earnings releasedThe company reported a solid third quarter result with improved earnings and revenues, although profit margins were weaker. Third quarter 2021 results: Revenue: ج.م899.3m (up 27% from 3Q 2020). Net income: ج.م87.8m (up 14% from 3Q 2020). Profit margin: 9.8% (down from 11% in 3Q 2020). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has fallen by 23% per year, which means it is performing significantly worse than earnings.
Reported Earnings • Aug 14Second quarter 2021 earnings releasedThe company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2021 results: Revenue: ج.م770.9m (up 12% from 2Q 2020). Net income: ج.م92.5m (up 325% from 2Q 2020). Profit margin: 12% (up from 3.2% in 2Q 2020). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 11% per year but the company’s share price has fallen by 22% per year, which means it is performing significantly worse than earnings.
Upcoming Dividend • Apr 18Inaugural dividend of ج.م2.95 per shareEligible shareholders must have bought the stock before 25 April 2021. Payment date: 28 April 2021. The company last paid an ordinary dividend in March 2018. The average dividend yield among industry peers is 4.3%.
Price Target Changed • Mar 25Price target decreased to ج.م64.07Down from ج.م68.90, the current price target is an average from 3 analysts. New target price is 49% above last closing price of ج.م43.12. Stock is down 26% over the past year.
Is New 90 Day High Low • Jan 18New 90-day low: ج.م42.53The company is down 10.0% from its price of ج.م47.00 on 20 October 2020. The Egyptian market is up 7.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 2.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ج.م36.24 per share.
Analyst Estimate Surprise Post Earnings • Nov 18Earnings beat expectations, revenue disappointsRevenue missed analyst estimates by 2.6%. Earnings per share (EPS) exceeded analyst estimates by 2.8%. Over the next year, revenue is forecast to grow 14%, compared to a 7.5% growth forecast for the Pharmaceuticals industry in Egypt.
Is New 90 Day High Low • Nov 16New 90-day high: ج.م48.51The company is up 2.0% from its price of ج.م47.60 on 18 August 2020. The Egyptian market is up 3.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ج.م31.61 per share.
Is New 90 Day High Low • Sep 30New 90-day low: ج.م45.00The company is down 15% from its price of ج.م52.90 on 30 June 2020. The Egyptian market is up 6.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 7.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ج.م31.61 per share.